Gemtuzumab ozogamicin for acute myeloid leukemia
2017年11月30日 · On 1 September 2017, the US Food and Drug Administration (FDA) approved gemtuzumab ozogamicin (GO) for the treatment of adults with newly diagnosed CD33 + acute …
肿瘤免疫靶点 | CD33 - 知乎 - 知乎专栏
Gemtuzumab ozogamicin （GO，辉瑞，CD33单抗+N-乙酰-卡奇霉素）是目前唯一获批上市靶向CD33的抗体药物。 （数据来源Walter RB, et al. Blood. 2012） GO曾在2000年就获得FDA批 …
CD33 Expression and Gentuzumab Ozogamicin in Acute Myeloid …
Gemtuzumab ozogamicin (GO), a humanized murine IgG4 anti-CD33 antibody, is the first target therapy approved in AML therapeutic scenario. This review focuses on current biological …
Gemtuzumab ozogamicin for treatment of newly diagnosed CD33 …
In September 2017, the US FDA announced re-approval of gemtuzumab ozogamicin (GO), a CD33-targeting immunoconjugate, for treatment of newly diagnosed and relapsed/refractory …
Gemtuzumab ozogamicin and novel antibody-drug conjugates in …
2019年10月31日 · Single-agent GO is effective and safe for AML patient ineligible for intensive chemotherapy. Multiple combination regimens incorporating GO have also been …
Gemtuzumab ozogamicin for treatment of newly diagnosed CD33 …
In September 2017, the US FDA announced re-approval of gemtuzumab ozogamicin (GO), a CD33-targeting immunoconjugate, for treatment of newly diagnosed and relapsed/refractory …
血液肿瘤靶点-CD33/Siglec-3 - 专注肿瘤免疫
2024年8月16日 · Gemtuzumab ozogamicin（GO，辉瑞，CD33 单抗 +N- 乙酰 – 卡奇霉素）是目前唯一获批上市靶向CD33的抗体药物。 GO 曾在 2000 年就获得 FDA 批准（第一款获批的 …
吉妥珠单抗在CD33阳性急性髓系白血病中的研究进展
吉妥珠单抗（gemtuzumab ozogamicin，GO）是一种由人源化抗CD33单抗与脱氧核糖核酸（deoxyribonucleic acid，DNA）嵌入剂卡奇霉素（calicheamicin，CLM）形成的抗体偶联药物 …
当患者接受2 mg/m2以上的GO时， CD33可达90%以上的饱和度，且在第1次用药后72 h 内，CD33可以在细胞表面快速循环和重新表达[4, 9]。 因此，3 d接受1次低剂量GO治疗可以 …
Gemtuzumab ozogamicin in acute myeloid leukemia | Leukemia
2017年6月13日 · Efforts to target CD33 therapeutically have focused on gemtuzumab ozogamicin (GO; Mylotarg), an antibody-drug conjugate delivering a DNA-damaging calicheamicin …